Tesamorelin

Tesamorelin is a synthetic GHRH analogue that features a unique trans-3-hexenoic acid modification at the N-terminus, which enhances metabolic stability and resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). It stimulates pulsatile GH release from the anterior pituitary, resulting in physiological GH and IGF-1 elevation without suppressing endogenous GHRH signaling. Tesamorelin is notable for being one of the few GHRH analogues to have undergone extensive Phase III clinical evaluation, with published data demonstrating significant reductions in visceral adipose tissue (VAT), improvements in trunk fat distribution, and favorable effects on lipid profiles including triglyceride reduction. Research has also explored its effects on hepatic fat content, liver fibrosis biomarkers, and cognitive function in aging populations. Additionally, studies have investigated its effects on body composition parameters including trunk fat-to-limb fat ratios and the relationship between VAT reduction and cardiovascular risk biomarkers. The 20 mg format supports multi-dose research protocols in metabolic and endocrine studies.